Neomyci (Neo-Fradin, Mycifradin)
Supportive Care · Approved since 1964
Description
Neomycin is an aminoglycoside antibiotic used as part of bowel preparation protocols prior to colorectal cancer surgery. It is administered orally to reduce the bacterial load in the gastrointestinal tract, thereby decreasing the risk of surgical site infections during colorectal procedures. In CRC treatment, neomycin serves a supportive role by helping to sterilize the bowel before operative intervention rather than providing direct anti-cancer therapy.
Mechanism of Action
Neomycin works by binding to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and ultimately leading to bacterial cell death. When used for bowel preparation, it selectively reduces gram-negative enteric bacteria in the colon, creating a more sterile surgical field and reducing the risk of postoperative complications from bacterial translocation.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Neo-Fradin, Mycifradin |
| Category | Supportive Care |
 Status | FDA Approved |
| Administration | Oral |
| Year Approved | 1964 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.